77413 RA KRE Department for Cancer Treatment Cell Prosthesing Equipment

ion for Cell Therapy (SfC), Oslo University Hospital (OUS). The contracting authority intends to procure two (2) units of Cellsaver Xtra from LivaNova AS. The estimated annual usage is 15 procedures. Please refer to the attached detailed justification. In light of the technical requirements, the nee

d for methodological validation, and regulatory considerations, LivaNova AS is assessed to be the only supplier capable of fulfilling the requirements. The conditions for applying the negotiated procedure without prior publication, pursuant